Rx Name [NEVIRAPINE, 08180816]

Rx Name	NEVIR 200MG TAB (EMC/COL) NEVIRAPINE
Active Ingredient	NEVIRAPINE
Therapeutic Code	08180816
Therapeutic Class	NNRTI
Indications	For use in combination with other antiretroviral agents for the treatment of HIV-1 infection. Nevirap ine reduces maternal to fetal HIV transmission.
Caution	Nevirapine is generally well-tolerated. The primary adverse effects are fever, nausea, and headache. However severe and life-threatening skin reactions, toxic epidermal necroly sis and Stevens-Johnson syndrome have been reported. Women appear to be at higher risk for hepatic events.
Dose Range	Adult: 200mg once daily for 14 day s, then increased to 200mg twice daily , in ombination with a nucleoside analogue antiretroviral agent. Pediatric: 2 months to 8 y ears: 4mg/kg/day for the first 14 day s followed by 7mg/kg twice daily . 8 y ea
Drug Interactions
Pregnancy	The human pregnancy data for nevirapine suggest that the risk for embryo–fetal harm is low. At least at term, the drug readily crosses the human placenta. If indicated, the drug should not be withheld because of pregnancy
Breast Feeding	The Centers for Disease Control and Prevention (CDC) and other experts recommend that HIV-infected women not breast-feed infants, regardless of antiretroviral therapy due to the risk of transmitting the virus through breastfeeding.
Drug Note